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Summary
In the past, the skills required to make an accurate dermatological diagnosis have
required exposure to thousands of patients over many years. However, in recent
years, artificial intelligence (AI) has made enormous advances, particularly in the
area of image classification. This has led computer scientists to apply these tech-
niques to develop algorithms that are able to recognize skin lesions, particularly
melanoma. Since 2017, there have been numerous studies assessing the accuracy of
algorithms, with some reporting that the accuracy matches or surpasses that of a
dermatologist. While the principles underlying these methods are relatively
straightforward, it can be challenging for the practising dermatologist to make sense
of a plethora of unfamiliar terms in this domain. Here we explain the concepts of
AI, machine learning, neural networks and deep learning, and explore the principles
of how these tasks are accomplished. We critically evaluate the studies that have
assessed the efficacy of these methods and discuss limitations and potential ethical
issues. The burden of skin cancer is growing within the Western world, with major
implications for both population skin health and the provision of dermatology ser-
vices. AI has the potential to assist in the diagnosis of skin lesions and may have par-
ticular value at the interface between primary and secondary care. The emerging
technology represents an exciting opportunity for dermatologists, who are the indi-
viduals best informed to explore the utility of this powerful novel diagnostic tool,
and facilitate its safe and ethical implementation within healthcare systems.
What is already known about this topic?
• There is considerable interest in the application of artificial intelligence to
medicine.
• Several publications in recent years have described computer algorithms that can
diagnose melanoma or skin lesions.
• Multiple groups have independently evaluated algorithms for the diagnosis of mela-
noma and skin lesions.
What does this study add?
• We combine an introduction to the field with a summary of studies comparing
dermatologists against artificial intelligence algorithms with the aim of providing a
comprehensive resource for clinicians.
• This review will equip clinicians with the relevant knowledge to critically appraise
future studies, and also assess the clinical utility of this technology.
• A better informed and engaged cohort of clinicians will ensure that the technology
is applied effectively and ethically.
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In the last decade, a combination of novel computational
approaches, increases in available computing capacity and
availability of training data has facilitated the application of
powerful mathematical algorithms in the field of artificial
intelligence (AI). This has led to dramatic advances in the
performance of computers in tasks that have previously only
been possible for humans. Methods that can make predic-
tions of data without direct human intervention in the train-
ing process are referred to as machine learning. Image
classification has been at the forefront of machine learning
research, and as visual pattern recognition plays a larger role
in dermatology than perhaps in any other medical specialties,
early clinical applications of machine learning have been
within this specialty.
What are artificial intelligence and machine
learning?
AI is difficult to define precisely. In Alan Turing’s seminal
paper ‘Computing machinery and intelligence’, he proposed
the well-known Turing test, whereby a machine is deemed
intelligent if it is indistinguishable from a human in con-
versation by an impartial observer.1 In modern parlance,
artificial general intelligence refers to the ability of a
machine to communicate, reason and operate independently
in both familiar and novel scenarios in a similar manner to
a human. This remains far beyond the scope of current
methods and is not what is being referred to when the
term ‘AI’ is commonly used. Most references to AI are now
often used as an interchangeable term with ‘machine learn-
ing’ or ‘deep learning’, the latter being a specific form of
machine learning that is discussed in more detail below
(see Table 1 for a glossary of terms). Machine learning
refers to algorithms and statistical models that learn from
labelled training data, from which they are able to recog-
nize and infer patterns (Figure 1).
Generally, during the training of a machine learning model
a subset of the data is ‘held back’ and then subsequently used
for testing the accuracy of the trained model. The accuracy
of the model is assessed on this test dataset according to its
accuracy in correctly matching an image to its label, for
example melanoma or benign naevus. In any classification
system there will be a trade-off between sensitivity and speci-
ficity; for example, an AI system may output a probability
score for melanoma between 0 and 1, and this would require
the operator to set a threshold for the decision boundary. At
a low threshold, a higher proportion of melanomas will be
captured (high sensitivity) but there is a risk of classifying
benign naevi as malignant (low specificity). As the threshold
is increased, this would decrease the sensitivity, but increase
the specificity (i.e. fewer benign naevi classified as mela-
noma). The behaviour of a machine learning classifier in
response to changing the threshold can be visualized as a
receiver operating characteristic (ROC) curve. The greater the
area under the curve, the more accurate the classifier (Fig-
ure 2).
Deep learning and neural networks
Neural networks (Figure 3) pass input data through a series
of interconnected nodes (analogous to biological neurons).
Each node functions as a mathematical operation (addition,
multiplication, etc.), and a group of interconnected nodes
within the network is referred to as a ‘layer’ within a net-
work, with the overall structure of the layers being referred to
as the ‘architecture’. During training, every node is adjusted
and optimized through an iterative process called ‘backpropa-
gation’,2,3 allowing the neural network to improve its classifi-
cation accuracy.
Neural networks with multiple ‘hidden layers’ of nodes
(Figure 3) are referred to as ‘deep’ neural nets and perform
‘deep learning’. Although the concept of deep neural networks
was described decades ago, lack of affordable and efficient
Table 1 Essential terminology in the field of machine learning and
artificial intelligence
Artificial
intelligence (AI)
The ability of machines, such as computers,
to simulate human intelligence
Machine learning Algorithms and statistical models that are
programmed to learn from data, therefore
recognizing and inferring patterns within
them. This enables computers to perform
specific tasks without explicit instructions
from a human operator
Supervised
learning
Refers to machine learning tasks whereby
the goal is to identify a function that best
maps a set of inputs (e.g. image) to their
correct output (label). This is based
learning or training on prematched pairs.
This is in contrast to unsupervised
learning, where novel patterns such as
groups or ‘clusters’ are identified in data
without influence from prior knowledge
or labelling
Overfitting A common problem in machine learning
where the model has high accuracy when
tested on data from the same source as its
training data, but its performance does
not generalize to novel sources of data
Neural network A form of supervised machine learning
inspired by biology whereby data pass
through a series of interconnected
neurons, which are individually weighted
to make predictions. During training, the
data pass through the network in an
iterative manner and the weightings are
continually adjusted to optimize its ability
to match label to data
Deep learning Refers to a neural network with multiple
layers of ‘neurons’ that have adjustable
weights (mathematical functions)
Convolutional
neural network
Refers to a type of neural network whereby
the layers apply filters for specific features
to areas within an image
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computing power was a major limitation in being able to
train them effectively. However, in 2013 it was recognized
that graphical processing units (GPUs), originally designed for
three-dimensional graphics in computer games, could be
repurposed to power the repetitive training required for neu-
ral networks.4,5 Of note, convolutional neural networks
(CNNs) are a specific form of deep learning architecture that
have proven effective for the classification of image data.
CNNs have massively increased in popularity as a method for
computer-based image classification after the victory of the
GPU-powered CNN AlexNet in 2012, which won the Ima-
geNet competition with a top 5 error rate of 153%, which
was a remarkable 10% improvement on the next best
competitor.5
In the past few years, use of CNNs in classification tasks has
exploded due to demonstrable and consistently superior effi-
cacy and availability. Novel CNN architectures have been
developed, improved and made available for public use by
institutions with a high level of expertise and computational
resources; examples of these include ‘Inception’ by Google
and ‘ResNet’ by Microsoft. These architectures can be accessed
using software such as TensorFlow (developed by Google) or
PyTorch (developed by Facebook) and then trained further for
a specific purpose or used in a novel application. A common
approach would be to take a pretrained image recognition net-
work architecture such as Inception, and specialize its applica-
tion by inputting a specific type of image data. This process is
referred to as transfer learning.
The application of convolutional deep learning
in dermatology
Classifying data using CNNs is now relatively accessible, com-
putationally efficient and inexpensive, hence the explosion in
so-called ‘artificial intelligence’. In medicine to date, the main
areas of application have been the visual diagnostic specialties
of dermatology, radiology and pathology. Automating aspects
of dermatology with computer-aided image classification has
been attempted in dermatology for over 30 years;6–8 however,
previous efforts have achieved only limited accuracy. Although
attempts have been made in recent years to use neural net-
works to diagnose or monitor inflammatory dermatoses,9–11
these have generally not been as successful or impressive as
the networks constructed to diagnose skin lesions, particularly
Labelled training data
Malignant
Benign
Algorithm
‘Malignant’
‘Benign’
TRAINING TESTING
Predicted label
Unlabelled 
test data
Figure 1 Schematic depicting how a machine learning algorithm trains on a large dataset to be able to match data to label (supervised learning),
the performance of which can then be assessed.
Sensitivity
Sensitivity = True Positive Rate
Specificity = True Negative Rate
Receiving Operator Characteristics
Area Under Curve (AUROC) = 
= Perfect Performance 
(100% Sensitivity, 100% Specificity)
Figure 2 Schematic of a receiver operating characteristic (ROC) curve, which is a way of visualizing the performance of a trained model’s
sensitivity and specificity. Typically, machine learning studies will use ROC curves and calculations of the area under the curve (AUC or AUROC)
to quantify accuracy. The dashed line represents the desired perfect performance, when sensitivity and specificity are both 100%; in this scenario,
the AUC would be 10. In reality, there is a trade-off between sensitivity and specificity, which gives rise to a curve.
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melanoma. Melanoma is therefore the focus of the remainder
of this review, and Table S1 (see Supporting Information)
summarizes these head-to-head comparison studies.12–21
In 2017, Esteva et al. published a landmark study in Nature
that was notable for being the first to compare a neural net-
work’s performance against dermatologists.14 They used a pre-
trained GoogLeNet Inception v3 architecture and fine-tuned
the network (transfer learning) using a dataset of 127 463
clinical and dermoscopic images of skin lesions (subsequent
studies have shown it is possible to train networks on signifi-
cantly smaller datasets, numbering in the thousands). For test-
ing, they selected a subset of clinical and dermoscopic images
confirmed with biopsy and asked over 20 dermatologists for
their treatment decisions. Dermatologists were presented with
265 clinical images and 111 dermoscopic images of ‘ker-
atinocytic’ or ‘melanocytic’ nature, and asked whether they
would: (i) advise biopsy or further treatment or (ii) reassure
the patient. They inferred a ‘malignant’ or ‘benign’ diagnosis
from these management decisions, and then plotted the der-
matologists’ performance on the network’s ROC curves with
regards to classifying the keratinocytic or melanocytic lesions
(which were subdivided as dermoscopic or clinical) as ‘be-
nign’ or ‘malignant’ (Figure 4a). In both ‘keratinocytic’ and
‘melanocytic’ categories, the average dermatologist performed
at a level below the CNN ROC curves, with only one individ-
ual dermatologist performing better than the CNN ROC curve
in each category. This suggests that in the context of this
study, the CNN has superior accuracy to dermatologists.
A recently published large study detailed in two papers by
Brinker et al.19,20 involved training a ‘ResNet’ model on the
publicly available International Skin Imaging Collaboration
(ISIC) database,22 which contains in excess of 20 000 labelled
dermoscopic images and is required to meet some basic qual-
ity standards. This network was trained on over 12 000
images to perform two tasks: the first was to classify dermo-
scopic images of melanocytic lesions as benign or malignant
(Figure 4b), and the second was to classify clinical images of
melanocytic lesions as benign or malignant (Figure 4c). The
dermatologists were assessed using 200 test images, with the
decision requested mirroring that of the study of Esteva et al.:
to biopsy/treat or to reassure. Additionally, the dermatolo-
gists’ demographic data, such as experience and training level,
were requested.
The method used to quantify the relative performance also
consisted of drawing a mean ROC curve by calculating the
average predicted class probability for each test image (Fig-
ure 4b, c). The dermatologists’ performance for the same set
of images was then plotted on the ROC curve. Barring a few
individual exceptions, the dermatologists’ performance fell
below the CNN ROC curves in both the clinical and dermo-
scopic image classifications. The authors also used a second
approach, whereby they set the sensitivity of the CNN at the
level of the attending dermatologists, and compared the mean
specificity achieved at equivalent sensitivity. In the dermo-
scopic test, at a sensitivity of 741%, the dermatologists’ speci-
ficity was 60% whereas the CNN achieved a superior 865%.
As part of an international effort to produce technology for
early melanoma diagnosis, in 2016 an annual challenge was
established to test the performance of machine learning algo-
rithms using the image database from the ISIC.22 A recent
paper by Tschandl et al.21 summarizes the performance of the
most recent competition in August to September 2018, and
Melanoma
Naevus
Figure 3 Schematic depicting how classification tasks are performed in convolutional neural networks. Pixel data from an image are passed
through an architecture consisting of multiple layers of connecting nodes. In convolutional neural networks, these layers contain unique
‘convolutional layers’, which operate as filters. These filters work because it was recognized that the location of a feature within an image is often
less important than whether that feature is present or absent – an example might be (theoretically) the presence or absence of blue-grey veiling
within a melanoma. A convolutional ‘filter’ learns a particular feature of the image irrespective of where it occurs within the image (represented
by the black squares). The network is composed of a large number of hierarchical filters that learn increasingly high-level representations of the
image. These could in principle learn dermoscopic features similar to those described by clinicians, although in practice the precise features
recognized are likely to differ from classic diagnostic criteria.
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(a) Esteva et al.
(b) Brinker et al., dermoscopic images (c) Brinker et al., clinical images
(d) Tschandl et al.
Figure 4 Receiver operating characteristic (ROC) curves from studies by Esteva et al.,14 Brinker et al.19,20 and Tschandl et al.21 Most often, the
dermatologists’ comparative ROC curves are plotted as individual data points. Lying below the curve means that their sensitivity and specificity,
and therefore accuracy, are considered inferior to those of the model in the study. The studies all demonstrate that, on average, dermatologists sit
below the ROC curve of the machine learning algorithm. It is noticeable that the performance of the clinicians in Brinker’s studies (b, c), for
example, is inferior to that of the clinicians in the Esteva study (a). Although there is a greater spread of clinical experience in the Brinker studies,
the discrepancy could also be related to how the clinicians were tested. In both Brinker’s and Tschandl’s studies, some individual data points
represent performance discrepancy that is significantly lower than data would suggest in the real world, which could suggest that the assessments
may be biased against clinicians. AUC, area under the curve; CNN, convolutional neural network. All figures are reproduced with permission of
the copyright holders.
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also compares the performance of the submitted algorithms
against 511 human readers recruited from the World Der-
moscopy Congress, who comprised a mixture of board-certi-
fied dermatologists, dermatology residents and general
practitioners (Figure 4d). Test batches of 30 images were gen-
erated to compare the groups, with a choice of seven diag-
noses as multiple-choice questions provided. When comparing
all 139 algorithms against all dermatologists, dermatologists
on average achieved 17 out of 30 on the image multiple-
choice questions, whereas the algorithms on average achieved
19. As expected, years of experience improved the probability
for making a correct diagnosis. Regardless, the top three algo-
rithms in the challenge outperformed even experts with > 10
years of experience, and the ROC curves of these top three
algorithms sit well above the average performance of the
human readers.
Key biases, limitations and risks of automated
skin lesion classification
Given that, remarkably, all of the published studies indicate
superiority of machine learning algorithms over dermatolo-
gists, it is worth exploring the biases commonly found in
these study designs. These can be categorized into biases that
favour the networks and biases that disadvantage clinicians.
With regards to the first category, it is first worth noting that
in the studies described, the neural networks were generally
trained and tested on the same dataset. This closed-loop sys-
tem of training and testing highlights a common limitation
within machine learning called ‘generalizability’. On the occa-
sions that generalizability has been tested, neural networks
have often been found lacking. For example, Han et al.
released their neural network, which was a Microsoft ResNet-
152 architecture trained on nearly 20 000 skin lesion images
from a variety of sources as a web application.15 When Navar-
ette-Dechent et al. tested the network on data from the ISIC
dataset, which the network had not previously been exposed
to, its performance dropped from a reported area under the
curve of 091, to achieving the correct diagnosis in only 29
out of 100 lesions, which would imply a far lower area under
the curve.23 As algorithms are fundamentally a reflection of
their training data, this means that if the input image dataset
is biased in some way, this will have a direct impact on algo-
rithmic performance, which will only be apparent when they
are tested on completely separate datasets.
Another important limitation of the methodology used to
compare AI models with dermatologists is that ROC curves,
although a useful visual representation of sensitivity and speci-
ficity, do not address other important clinical risks. For exam-
ple, in order to capture more melanomas (increased
sensitivity), the algorithm may incorrectly misclassify more
benign naevi as malignant (false-positives). However, this
could potentially lead to unnecessary biopsies for patients,
which aside from patient harm would create additional
demand on an already burdened healthcare system. There is
evidence that dermatologists have improved ‘number need to
biopsy’ metrics for melanoma in comparison with nonderma-
tologists.24 The reporting of number need to biopsy would be
a useful addition to studies such as that of Esteva et al.,14 as it
would aid in the estimation of potential patient and health
economic impact.
It is also worth noting that these datasets are retrospectively
collated and repurposed for image classification training; this
means that the images captured may not be representative in
terms of the proportion of diagnoses, or in terms of having
typical features. As neural networks are essentially a reflection
of their labelled data input, this will undoubtedly have conse-
quences on how they perform. However, given the lack of
History
Examination
Neural network assessment
Decision
Refer urgently
Refer routinely
Reassure
Figure 5 Schematic showing hypothetical use of a machine learning algorithm to help nonexpert clinicians risk-stratify lesions to make clinical
decisions. Clinicians routinely weigh up both the benefits and limitations of common diagnostic aids such as prostate-specific antigen or D-dimers.
Currently, there are very few useful dermatological diagnostic decision aids available to nonexpert clinicians, as the diagnostic process is
dominated by image recognition. Convolutional neural network could represent a new class of decision aid that could help nonexpert clinicians
triage appropriately and narrow down their differential diagnosis.
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‘real-world’ studies, it is difficult to know how significant this
is. When it comes to assessing clinicians using images from
these datasets, this may also introduce an element of bias that
disadvantages clinicians too, as lesions that were deemed wor-
thy of capturing via photograph or being biopsied may not be
representative of the lesion type. As a result, the sensitivity of
clinicians diagnostically may be lower than in a normal clinic.
This hypothesis for discrepancy in diagnostic accuracy was
borne out in a recent Cochrane review, where the diagnostic
sensitivity of dermatologists examining melanocytic lesions
with dermoscopy was 92%,25 which is significantly higher
than typically found in neural network studies. For example in
Tschandl et al.’s web-based study of 511 clinicians, the sensi-
tivity of experts was 812%.22 The manner in which clinical
decisions are inferred as ‘benign’ or ‘malignant’ also makes
some assumptions that may not be accurate; for example, a
dermatologist’s decision to biopsy a lesion is a reflection of
risk, not an outright ‘malignant’ classification.
From a safety perspective, there are two considerations that
have yet to be addressed in the studies. Firstly, in order to ‘re-
place’ a dermatologist, an algorithm must be able to match
the current gold standard for screening a patient’s skin lesions.
Currently, this is a clinical assessment by a dermatologist, who
examines the lesion in the context of patient history and the
rest of their skin. Published studies do not compare neural
networks against this standard of assessment; they are only
compared with dermatologists presented with dermoscopic or
clinical images, sometimes with limited additional clinical
information. Not only does this bias the studies against der-
matologists, who are not trained or accustomed to make diag-
noses without this information, it also represents a limiting
factor in justifying their deployment in a clinical setting as a
replacement for dermatologists. Fundamentally, it has not yet
been demonstrated that they are equivalent to the standard of
dermatological care currently provided to patients. A second
important consideration is the fact that training data lack suffi-
cient quantities of certain types of lesions, particularly the
rarer presentations of malignancy, such as amelanotic mela-
noma.15 It is not yet clear how algorithms will perform when
presented with entirely novel, potentially malignant lesions;
this has rare but significant safety implications for patients.
From a legal perspective, an issue that has yet to be fully
addressed is the lack of explainability by neural networks. Cur-
rently, it is not possible to know what contributes to their
decision-making process. This has led to criticisms and con-
cerns that neural networks function as ‘black boxes’ with
potential unanticipated and hard-to-explain failure modes. The
European Union’s General Data Protection Requirement speci-
fies explainability as a requirement for algorithmic decision
making, which is currently not achievable.26,27 Algorithmic
decision making also has uncertain status in the USA, where
the Food and Drug Administration have advised that until
there exists a body of evidence from clinical trials, clinical
decisions suggested by AI ought to be considered AI guided,
not AI provided, and liability would still rest with the
clinician.28
The AI-integrated health service of the future?
There are attempts to deploy ‘AI’ technologies within the
healthcare space within two main scenarios: direct to con-
sumer or public, and as a decision aid for clinicians. The
direct-to-consumer model already exists in some fashion;
there are smartphone apps such as SkinVision, which enable
individuals to assess and track their skin lesions. However,
currently such apps do not make accountable diagnoses and
usually explicitly state in their terms and conditions that
they do not provide a diagnostic service, and do not intend
to replace or substitute visits to healthcare providers. At pre-
sent, it is not yet clear what the benefits and risks of such
a tool are in terms of how frequently it provides false reas-
surance, and how frequently it recommends referral when
this is not needed. Although health data democratization has
benefits from the perspective of patient autonomy, it may
be that this does not translate to better health outcomes and
might instead lead to unnecessary concern and investiga-
tions. Moreover, fundamentally, healthcare is currently struc-
tured in such a way that responsibility and liability are
carried by the provider and not the patient, and as such
these apps do not have a clear-cut position in healthcare
infrastructure.
The current social and legal framework of healthcare is
better primed for incorporating AI as a decision aid for
clinicians, particularly in enhancing decision making by
nonspecialists (Figure 5). This could potentially be of great
use in dermatology services due to the ever-growing burden
of skin cancer. In the UK, there is a long-standing shortfall
of consultant dermatologists, and current workforce plan-
ning is insufficient to address this. The volume of skin can-
cers has a knock-on effect on patients with chronic
inflammatory skin diseases, essentially reducing their access
to dermatologists.
Dermatologists are also aware that generally, a high propor-
tion of referrals to dermatology with suspected skin cancer on
the urgent ‘2-week wait’ pathway do not require further
investigation and are actually immediately discharged. Many
of the lesions falling into this category are easily recognized
by dermatologists, but are not easily recognized by nonspe-
cialists. One could hypothesize that CNN-based applications
can aid a general practitioner service in triaging skin lesions
more effectively, and ensure that patients are managed by the
appropriate clinical services. Having a clinical user also miti-
gates many of the risks and limitations inherent to CNN-based
technologies, improving both the safety profile and the patient
experience.
The recently published Topol Review on ‘Preparing the
healthcare workforce to deliver the digital future’ states that
‘to reap the benefits, the NHS must focus on building a digi-
tally ready workforce that is fully engaged and has the skills
and confidence to adopt and adapt new technologies in prac-
tice and in context’. It also concludes that ‘the adoption of
technology should be used to give healthcare staff more time
to care and interact directly with patients’.29 In the context of
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dermatology, this very much holds true. Technology adoption
could improve clinical pathways, and enable our neediest
patients to access dermatology services more efficiently. It is
unlikely that they will threaten our profession; in reality they
represent an opportunity for personal learning, service
improvement and leadership that could be transformative for
our future healthcare system.
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